J&J starts two-dose trial of its COVID-19 vaccine candidate

LONDON: Johnson & Johnson launched a new large-scale late-stage trial on Monday to test a two-dose regimen of its experimental COVID-19 vaccine and evaluate potential incremental benefits for the duration of protection with a second dose.
The US drugmaker plans to enrol up to 30,000 participants for the study and run it in parallel with a one-dose trial with as many as 60,000 volunteers that began in September.